Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Huangdai tablets plus imatinib vs imatinib alone in Ph+ chronic myeloid leukemia (chronic phase)
CTR20160180Phase 3Suspended
- Sponsor
- Anhui Tiankang Pharmaceutical
- Start
- Apr 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Compound Huangdai Tablet in chronic myelogenous leukemia (CML), sponsored by Anhui Tiankang Pharmaceutical. Started Apr 2016; status: suspended.
02
Drugs
Compound Huangdai Tablet
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20160180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160180.